HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

VU0652957

mGlu4 positive allosteric modulator

Also Known As:

VU2957; valiglurax

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - VU0652957: 1

Experts

1.	Blobaum, Anna L: 1 article (03/2019)
2.	Bronson, Joanne J: 1 article (03/2019)
3.	Castelhano, Arlindo L: 1 article (03/2019)
4.	Chun, Aspen: 1 article (03/2019)
5.	Conn, P Jeffrey: 1 article (03/2019)
6.	Emmitte, Kyle A: 1 article (03/2019)
7.	Engers, Darren W: 1 article (03/2019)
8.	Engers, Julie L: 1 article (03/2019)
9.	Felts, Andrew S: 1 article (03/2019)
10.	Hopkins, Corey R: 1 article (03/2019)

Related Diseases

1.	Parkinson Disease (Parkinson's Disease) 03/14/2019 - "Based on its overall profile, VU2957 was evaluated as a preclinical development candidate for the treatment of Parkinson's disease." 03/14/2019 - "Discovery of VU2957 (Valiglurax): An mGlu4 Positive Allosteric Modulator Evaluated as a Preclinical Candidate for the Treatment of Parkinson's Disease."

Related Drugs and Biologics

1.	VU0652957